[2] Though, the World Health Organization (WHO) in 2013 recommended use for seasonal preventive in children at high risk in combination with sulfadoxine and pyrimethamine.

Among amodiaquine users, several rare but serious side effects have been reported and linked to variants in the CYP2C8 alleles.

People who are poor metabolizers of amodiaquine display lower treatment efficacy against malaria, as well as increased toxicity.

[18] About 3.6% of the population studied showed high risk for a poor reaction to or reduced treatment outcomes when treated with amodiaquine.

This information is useful in developing programs of pharmacovigilance in East Africa, and have important clinical considerations for prescribing antimalarial medications in regions with high CYP2C8 variant frequency.